Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELAX: Reduced Duration Hormone Therapy in High-Risk Prostate Cancer
NCT06818682Phase 2Recruiting
- Sponsor
- Tata Memorial Centre
- Start
- Feb 2025
- Primary completion
- Jan 2035
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abiraterone and enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Tata Memorial Centre. Primary endpoint: Disease-free survival at 5 years. Started Feb 2025; status: recruiting.
02
Drugs
abirateroneenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06818682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818682.